Current Medicinal Chemistry

Weber, L. (2002) The Application of Multi-Component Reactions in Drug Discovery. Current Medicinal Chemistry, 9, 1241-1253. 

Bandarage, U.K., Kuehne, M.E., GUck, S.D. (2001) Chemical Synthesis and Biological Evaluation of 18-Methoxycoronaridine (18-MC) as a Potential Anti-Addictive Agent. Current Medicinal Chemistry Central Nervous System Agents, 1, 113-123. 

Laurent, S., Boutry, S., Mahieu, I., Vander Elst, L. and Muller, R.N. (2009) Iron oxide based MR contrast agents from chemistry to cell labeling. Current Medicinal Chemistry, 16 (35), 4712-4727. 

Abourashed, E.A., Clark, A.M. and Hufford, C.D. (1999) Microbial models of mammalian metabolism of xenobiotics an updated review. Current Medicinal Chemistry, 6, 359-374. 

Shen, B., Liu, W. and Nonaka, K. (2003) Enediyne natural products biosynthesis and prospect towards engineering novel antitumor agents. Current Medicinal Chemistry, 10, 2317. 

Coradin, T., Boissiere, M. and Livage, J. (2006) Sol-gelchemistryin medicinal science. Current Medicinal Chemistry, 13, 99-108. 

Miller, A.D., The problem with cationic liposome/micelle-based non-viral vector systems for gene therapy, Current Medicinal Chemistry, 2003, 10, 1195-1211. 

Aboul-Fadt, T. 2005. Antisense oligonucleotides the state of the art. Current Medicinal Chemistry 12(19), 2193-2214. 

Bremner, J.B., Griffith, R. and Coban, B. (2001) Ligand design for alpha(l) adrenoceptors. Current Medicinal Chemistry, 8, 607-620. 

Perez-Tomas, R. (2006) Multidrug resistance retrospect and prospects in anti-cancer drug treatment. Current Medicinal Chemistry, 13, 1859-1876. 

Augustyns, K., der Veken, P.V., Senten, K. and Haemers, A. (2005) The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP-IV) and related proline-specific dipeptidyl aminopeptidases. Current Medicinal Chemistry, 12, 971-998 (c) Augustyns, K., der Veken, P.V. and Haemers, A. 

Efremov R.G. Chugunov A.O. Pyrkov T.V. Priestle J.P. Arseniev A.S. Jacoby E. Molecular lipophilicity in protein modeling and drug design. Current Medicinal Chemistry, 2007, 14, 393—415. 

Linusson A. Elofsson M. Andersson I.E. Dahlgren M.K. Statistical molecular design of balanced compound libraries for QSAR modeling. Current Medicinal Chemistry, 2010, 17 (19), 2001-2016. 

The structure and function of histone deacetylases The target for anticancer therapy. Current Medicinal Chemistry, 15, 2840-2849. 

Xie, A., Liao, C Li, Z., Ning, Z., Hu, W., Lu, X., Shi, L. and Zhou, J. (2004) Quantitative structure-activity relationship study of histone deacetylase inhibitors. Current Medicinal Chemistry Anticancer Agents, 4, 273-299. 

Warner, G., Illy, C., Pedro, L., Roby, P. and Bosse, R. (2004) AlphaScreen kinase HTS platforms. Current Medicinal Chemistry, 11, 721-730. 

Curtin, M. and Glaser, K (2003) Histone deacetylase inhibitors the Abbott experience. Current Medicinal Chemistry, 10, 2373-2392. 

Zhu, W.G. and Otterson, G.A. (2003) The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Current Medicinal Chemistry Anticancer Agents, 3, 187-199. 

Thai, K.-M. and Ecker, G.E. (2007) Predictive models for hERG channel blockers ligand-based and structure-based approaches. Current Medicinal Chemistry, 14, 3003-3026. 

Amacher, D.E. (2005) Drug-associated mitochondrial toxicity and its detection. Current Medicinal Chemistry, 12 (16), 1829-1839. 

Sultan, M., Stecher, G., Stoggl, W. M., Bakry, R., Zahorski, P, Huck, C. W., El Kousy, N. M., and Bonn, G. K., Sample pretreatment and determination of non steroidal anti-inflammatory drugs (NSAIDs) in pharmaceutical formulations and biological samples (blood, plasma, erythrocytes) by HPLC-UV-MS and micro-HPLC, Current Medicinal Chemistry 12(5), 573-588, 2005. 

Much of current medicinal chemistry concerning antipsychotics is exploring the various subtypes of DA receptors, and how specific or mixed antagonists at the various receptors can influence the natural history and course of major psychiatric illnesses. 

E. Rucker (1987). Structure, function and assembly of membrane proteins. Science 235 959-961. G. Schneider, W. Neidhart, G. Adam (2001). Integrating virtual screening methods to the quest for novel membrane protein ligands. Current Medicinal Chemistry Central Nervous System Agents 1 99-112. 

Small-molecule inhibitors of caspases would have obvious use as therapeutics. The current medicinal chemistry research literature is rich in studies attempting to achieve this important design goal. In early work, both reversible and irreversible peptide-based inhibitors of various caspases have been developed. Peptidomimetic ketones were also devised for example, acyloxymethyl ketones were designed and developed as potent, time-dependent irreversible caspase inhibitors. 

Kwon, H. J. (2003). Chemical genomics-based target identification and validation of anti-angiogenic agents. Current Medicinal Chemistry 10, 717-736. 

Gray, N., Detivaud, L., Doerig, C., Meijer, L. ATP-site directed inhibitors of cyclin-dependent kinases. Current Medicinal Chemistry 1999, 6, 859-875. 

---